Related Experiment Video
Updated: Jul 12, 2025

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
Published on: September 23, 2015
Serotonin Transporter mRNA Expression Is Reduced in the Peripheral Blood Mononuclear Cells of Subjects with Major
Gaël Villanueva-Charbonneau1,2, Stéphane Potvin2,3, Serge Marchand4
1Département de Pharmacologie et Physiologie, Université de Montréal, Montréal, QC H1T 1C8, Canada.
Background:
Fibromyalgia (FM) and major depression disorder (MDD) frequently co-occur. Both disorders may share common serotonergic alterations, although there is less evidence of such alterations in FM. It is also unclear as to whether these alterations are persistent over time or transient. The objectives of this study were to (i) examine the changes in mRNA expression of serotonin transporter (SERT) on the surface of peripheral blood mononuclear cells (PBMCs) in FM, MDD, and the FM + MDD subjects compared to healthy controls, and to (ii) evaluate the effect of drug treatment on SERT expression.
Methods:
PBMCs were isolated from FM, MDD, FM + MDD, and control subjects. SERT expression was analyzed at the mRNA level via quantitative real-time polymerase chain reaction. Statistical analyses were performed using analyses of variance and linear mixed-effects models.
Results:
SERT mRNA expression was significantly reduced in MDD subjects compared to controls (p < 0.001), but not in FM nor in FM + MDD subjects. Although the drug treatments improved symptoms in FM, MDD, and FM + MDD subjects, they had no significant effect on SERT mRNA expression.
Conclusions:
These results corroborate the role of the SERT in the pathophysiology of MDD, but not in FM, and show that the decreased mRNA expression of SERT is a persistent, rather than transient, phenomenon.
Insights
Serotonin transporter (SERT) mRNA expression is persistently reduced in major depression disorder (MDD) but not fibromyalgia (FM). Drug treatments did not alter SERT mRNA levels in these conditions.
Area of Science:
- Neuroscience
- Psychiatry
- Genetics
Background:
- Fibromyalgia (FM) and major depression disorder (MDD) frequently co-occur, potentially sharing serotonergic alterations.
- Evidence for serotonergic alterations in FM is limited, and their persistence over time is unclear.
Purpose of the Study:
- To examine changes in serotonin transporter (SERT) mRNA expression in peripheral blood mononuclear cells (PBMCs) of individuals with FM, MDD, or both, compared to controls.
- To evaluate the impact of drug treatment on SERT expression in these groups.
Main Methods:
- PBMCs were isolated from FM, MDD, FM + MDD, and control subjects.
- Quantitative real-time polymerase chain reaction was used to analyze SERT mRNA expression.
- Statistical analyses included analyses of variance and linear mixed-effects models.
Main Results:
- SERT mRNA expression was significantly reduced in MDD subjects compared to controls (p < 0.001).
- No significant reduction in SERT mRNA expression was observed in FM or FM + MDD subjects.
- Drug treatments improved symptoms but did not significantly affect SERT mRNA expression.
Conclusions:
- The findings support a role for SERT in the pathophysiology of MDD, but not FM.
- Decreased SERT mRNA expression appears to be a persistent characteristic in MDD, not a transient one.
More Related Videos
Related Concept Videos
G-protein Coupled Receptors
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Depressive Disorders: MDD and Dysthymia
Depressive Disorders: Etiology
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Depression: Overview

